Malaysia
Search
Sign In
Dermatology
Top Medical News
Use of long-pulsed neodymium-doped yttrium-aluminium-garnet (LP-Nd:YAG) laser provides similar overall therapeutic effects to those of cryotherapy, results of a recent study have shown. However, laser appears more effective against recalcitrant warts and results in shorter time to warts clearance.
Itraconazole appears to be effective in the treatment of patients with tinea corporis/cruris (TCC) or ringworm of the body, as shown in a study. However, the treatment duration needs to be longer and, even with successful treatment, many patients experience relapse.
New drug applications approved by US FDA as of 16 - 30 November 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
There appears to be low to no metastatic potential for melanocytic tumours of uncertain malignant potential (MELTUMP) and superficial atypical melanocytic proliferations of uncertain significance (SAMPUS), a recent study has found.
Inflammatory bowel disease appears to be a causal risk factor for both psoriasis and psoriatic arthritis, with Crohn’s disease specifically associated with the development of the two psoriasis outcomes, according to a study.
Hair and nail disorders may occur following contraction of COVID-19 infection, with the development of the dermatological conditions related to a history of severe infection, a study has found.
The use of ritlecitinib, an oral JAK3/TEC inhibitor, appears effective for the treatment of nonsegmental vitiligo (NSV) and is well-tolerated for over 48 weeks of follow-up, reports a recent study.
Special Reports
Bifonazole Anti-Fungal Cream 1% w/w
Furfuryl Palmitate
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
DCH Auriga recently held their first Aesthetics and Suturing Workshop under the IMPACT continuing medical education series – a scientific platform that aims to cascade the latest updates on disease management and share best clinical practices among healthcare professionals in Singapore. Two experts on aesthetics and aesthetic surgery shared their insights on suturing techniques and current approaches for scar prevention and management.
Eczema (atopic dermatitis) is a chronic inflammatory skin disease that
can present in many different forms. However, it is principally
characterized by dry skin, intense itching, and the presence of
inflammatory skin lesions. [J Eur Acad Dermatol Venereol
2016;30:604-618; N Engl J Med 2008;358:1483-1494; Lancet
2016;387:1109-1122]
Conference Reports
Predicting which newborn will go on to develop atopic dermatitis (AD) and how severe it will be is now feasible, according to the BABY* study.
Long-term use of ruxolitinib cream continued to improve facial and total body repigmentation in patients with nonsegmental vitiligo from 24 to 52 weeks, according to an updated pooled analysis of the phase III TRuE-V1* and TRuE-V2** studies presented at EADV 2022.
Dupilumab improves itch response and skin lesions in patients with prurigo nodularis (PN) inadequately controlled with prior therapies in the LIBERTY-PN PRIME trial.
Maintenance lebrikizumab monotherapy appears to improve outcomes in patients with moderate-to-severe atopic dermatitis (AD), according to results of the phase III ADvocate1 and ADvocate2 trials.
Ligelizumab, a next-generation anti-IgE antibody, is safe and effective in treating patients with H1-antihistamine (H1-AH) refractory chronic spontaneous urticaria (CSU), according to two phase III studies presented at EADV 2022.
The benefit of deucravacitinib in moderate to severe plaque psoriasis was demonstrated in a population of Asian patients, according to results of the phase III POETYK PSO-3 trial.
Rocatinlimab improved disease severity in patients with moderate-to-severe head and neck atopic dermatitis (H&N AD), a post hoc analysis of a phase IIb trial has shown.
